Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Véronique Dièras(Institut Curie), David Miles(Mount Vernon Cancer Centre), Sunil Verma(Sunnybrook Health Science Centre), Mark D. Pegram(Palo Alto Institute), Manfred Welslau(Klinikum Aschaffenburg), José Baselga(Memorial Sloan Kettering Cancer Center), Ian E. Krop(Dana-Farber Cancer Institute), Kim T. Blackwell(Duke Medical Center), Silke Hoersch(Roche (Switzerland)), Jin Xu, Marjorie Green, Luca Gianni
Cited by 652
Abstract
Related Papers
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al.|New England Journal of Medicine|2001|11.5k